The short version
- Why people research itFocus, memory, neuroprotection, mood and stress resilience.
- What the evidence isReached phase 2 in humans for major depressive disorder, run by Neuralstem.
- What to watchMood that worsens, or any thoughts of self-harm.
How NSI-189 works
Stimulates hippocampal neurogenesis and increases hippocampal volume; studied for depression and cognitive recovery.
NSI-189 is a small molecule with a published structure and no published target. The compound is NSI-189 phosphate, (4-benzylpiperazin-1-yl)-[2-(3-methyl-butylamino)pyridin-3-yl]methanone Liu 2019 — a benzylpiperazine joined by a ketone to an aminopyridine.
That is not an oversight. It is how the compound was found. It came out of a phenotypic screen for proliferation of human hippocampus-derived neural stem cells Liu 2019 — a screen that asks ‘does this make more cells?’ rather than ‘does this bind that?’.
- Oral
On the goal map: Glutamatergic & synaptic plasticity (Focus, memory & cognition)
Research on NSI-1895 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
Reached phase 2 in humans for major depressive disorder, run by Neuralstem. The trial missed its primary endpoint on the MADRS depression scale.
What did move is the part usually left out: secondary cognitive measures improved significantly, and patient-reported outcomes favored the drug. A later analysis argued the trial was underpowered for the effect size seen. That is a different situation from a compound that did nothing.
Correlative data
Community use for mood and cognition. Reported experience is of a slow onset over weeks, consistent with a neurogenesis mechanism rather than a monoamine one.
How the mechanism reads
A nicotinamide derivative that stimulates neurogenesis in the hippocampus — it increased hippocampal volume in rodent work, which is notable because hippocampal atrophy is a well-replicated finding in depression.
Experimental, animal or cellActing on neurogenesis rather than on serotonin is why the timescale is weeks and why the cognitive signal in the trial may be the more meaningful result.
Mechanistic
Sources
- Fava M, et al. Molecular Psychiatry 2016 · PMID 26643541
- Papakostas GI, et al. A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder. Molecular Psychiatry 2020 · PMID 30626911
- Johe KK, et al. NSI-189 phosphate, a novel neurogenic compound, selectively benefits moderately depressed patients: A post-hoc analysis of a phase 2 study of major depressive disorder. Annals of Clinical Psychiatry 2020 · PMID 32722729
- Jolivalt CG, et al. Amelioration of Both Central and Peripheral Neuropathy in Mouse Models of Type 1 and Type 2 Diabetes by the Neurogenic Molecule NSI-189. Diabetes 2019 · PMID 31492662
- Jolivalt CG, et al. Enhancement of Mitochondrial Function by the Neurogenic Molecule NSI-189 Accompanies Reversal of Peripheral Neuropathy and Memory Impairment in a Rat Model of Type 2 Diabetes. Journal of Diabetes Research 2022 · PMID 35967127
- Liu Y, et al. Enhancement of synaptic plasticity and reversal of impairments in motor and cognitive functions in a mouse model of Angelman Syndrome by a small neurogenic molecule, NSI-189. Neuropharmacology 2019 · PMID 30408487
NSI-189 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Age under 25 or any suicidal thoughts: neuroactive antidepressant-class compounds can raise risk early.
- Bipolar disorder: an antidepressant-type effect can switch mood toward mania.
- SSRIs, MAOIs or other serotonergic drugs: interaction data are missing.
- Pregnancy: promoting hippocampal neurogenesis has no fetal safety data.
- Seizure history: the phase 2 trials excluded it.
What’s expected
- Possible slow mood and thinking benefit over weeks, if the neurogenesis mechanism holds.
- Headache or fatigue, common early with neuroactive small molecules.
- Light nausea or sleep changes.
Watch for
- Mood that worsens, or any thoughts of self-harm.
- Several days of unusually high energy with little sleep.
- A seizure.
- Intense restlessness.
Labs that tell you it’s working
- TSH (Thyroid-Stimulating Hormone)
- Vitamin D (25-Hydroxy)
- Vitamin B12 & Folate
- Comprehensive Metabolic Panel (CMP)
NSI-189 stimulates hippocampal neurogenesis; its phase 2 results were mixed, and mood-relevant labs rule out other causes of low mood. PMID 30626911 PMID 26643541
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
NSI-189 FAQ4 common questions
- Is NSI-189 approved for human use?
- No. NSI-189 is a research compound.
- What is NSI-189 researched for?
- Focus, memory, neuroprotection, mood and stress resilience.
- Which labs show whether it's doing anything?
- TSH; Vitamin D; Vitamin B12 & Folate; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for NSI-189: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



